KDR and chordoma: Anlotinib (multi-target TKI that inhibits VEGFR, FGFR, PDGFR, KIT, and RET) was evaluated by a multiple-institution retrospective study in 48 patients with advanced sarcomas including 27 OS, eight ES, nine CS, and three chordomas [118].